Beyond 1L EGFRm mNSCLC Management: Today’s Challenges, Tomorrow’s Approach
HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGFRm Advanced NSCLC
By
UCLA Health
FEATURING
Aaron Lisberg
By
UCLA Health
FEATURING
Aaron Lisberg
Login to view comments.
Click here to Login
